Recruitment on C-BOBCAT pilot cancer trial closed for Clarity’s SAR-Bombesin product
Sydney, Australia 19 October 2021 C-BOBCAT breast cancer trial of Clarity’s SAR-Bombesin product closes for recruitment. The diagnostic program with 64Cu SAR-Bombesin generated evidence of the utility and potential superiority in some patient subgroups compared to conventional imaging (e.g. 99mTc bone scan, 18F FDG). The high uptake and strong product retention visualised by PET imaging…